Introduction
Acute lymphoblastic leukaemia (ALL) is the most frequent childhood cancer. During the last 50 years its prognosis has improved from zero probability of survival in the 1950s to more than 80% chance to be cured at the beginning of the 21st century. ALL is a highly chemosensitive disease and its successful treatment is a good indicator of the level of medical care that children with cancer get in each country. Th ere are huge diff erences in the outcome of this disease between developed and developing countries. For some of them it was a fi rst experience with participation in an international randomized trial using a common database. Th e fi nal results of this study will be published in a near future.
Several Middle/East European countries participating in trial ALL IC-BFM 2002 accepted the invitation to present their pre-ALL IC experience in the diagnosis and treatment of childhood ALL in MEMO journal published according to a common concept. Historically, paediatric oncologists from East-European countries suff ered from a lack of contacts with their West-European colleagues during long-lasting communist rule in this part of Europe. During these diffi cult years of life in totalitarian systems they had limited access to the medical information about new diagnostic and treatment modalities. Despite relatively good standard of general paediatrics in some of these countries, the paediatric oncology generally suff ered from lack of fi nancial resources not only for research and expensive diagnostic procedures, but more importantly also for the purchase of the expensive anticancer drugs, antibiotics etc. Middle/East Europe is composed of a very heterogeneous group of countries. Despite sharing many similarities, it is certainly true that the starting point was very diff erent for the individual countries at the beginning of the1990s after the end of communism in this part of Europe. According to Eurocare data, the probability of 5-yr overall survival of children with cancer was signifi cantly lower in East Europe (45-65%) in comparison with West Europe (5-yr OS 71-81%) in the fi rst half of the 1990s [1] . Th e recent survey of the SIOPE Board (European branch of the International Paediatric Oncology Society) showed that entry into clinical trials was more consistent in Western rather than in Eastern European countries in the 1990s. EastEuropean paediatric oncologists suff ered from lack of experience in performing controlled clinical studies, lack of health professionals trained in Good Clinical Practice. Great reduction of mortality has been achieved in the 1990s and at the beginning of the 21st century in the Eastern European countries. Further improvement will be slower and a necessary infrastructure for it has to be established. Multi-disciplinary skilled teams have to be built and equipped. Th ey are required for the complex care of childhood cancer patients and to warrant further improvements in survival.
Papers coming from Poland [2] , Czech Republic [3] , Slovakia [4] , Slovenia [5] and Serbia [6] will introduce the history of nationally unifi ed treatment of childhood ALL in each country before the ALLIC study has been launched. Despite all diffi culties, the paediatric oncologists have done their best to give chance of cure to children with ALL also in this part of Europe. I am sure the readers will agree on it.
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